Jason Ehrlich
Plus aucun poste en cours
Fortune : 325 720 $ au 31/03/2024
Profil
Jason S. Ehrlich occupe le poste de directeur médical et du développement chez Kodiak Sciences, Inc. Dans sa carrière antérieure, le Dr Ehrlich a occupé le poste de Global Head-Clinical Ophthalmology chez Genentech, Inc. Il a obtenu un diplôme de premier cycle à l'université de Princeton et un doctorat à la faculté de médecine de l'université de Stanford.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
KODIAK SCIENCES, INC.
0,12% | 24/06/2023 | 61 924 ( 0,12% ) | 325 720 $ | 31/03/2024 |
Anciens postes connus de Jason Ehrlich
Sociétés | Poste | Fin |
---|---|---|
KODIAK SCIENCES INC. | Chief Tech/Sci/R&D Officer | 25/08/2023 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/01/2018 |
Formation de Jason Ehrlich
Princeton University | Undergraduate Degree |
Stanford University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
KODIAK SCIENCES INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |